U54AG089326
Cooperative Agreement
Overview
Grant Description
Vanderbilt-Coordinated Human Virome Collaborative Center (V2C2) - Viruses are responsible for significant morbidity/mortality at the heart of most of global pandemics of the 21st century.
Recent developments in technical and bioinformatic capabilities to address viral sequence diversity in a high-throughput context alongside integrated host responses have ushered in the potential for investigating viral presence and consequences at epidemiologic scale.
Here, we establish the Vanderbilt-Coordinated Virus Characterization Center (V2C2) to respond to RFA-RM-23-019 to address the central call of the Human Virome Program (HVP)—to provide a comprehensive, annotated, host-contextualized virome.
The central theme/hypothesis of V2C2 is that unrecognized eukaryotic/prokaryotic viruses in human ecology (1) exhibit important interactions with host biology and flora, with prevalence of viral persistence or integration related to variation in biologically relevant phenotypes in healthy individuals (e.g., obesity, inflammation).
To address this hypothesis, we will study (1) ≈2250 Hispanic/Latinx individuals at the US-Mexico border (ages 8-90; 1750 with 2 serial samples already collected with up to ≈20 years follow-up; 500 with 3 serial samples to be prospectively collected over ≈4 years); (2) ≈200 children (ages 0-5, CANOE-VU) with serial samples (some already collected).
We propose a broad sampling scheme for prospective samples, spanning ocular, nasal, oropharyngeal, plasma, blood (extracellular vesicles, PBMCs, platelets), urine, and stool samples, and accompanying placental and breast milk samples (pediatric cohort), and will prioritize plasma (all samples) and 3 additional sample types (prospective only) based on consortium discussion.
Our host-contextualized viral characterization approach (Aim 1) will include viral whole metagenomic/metatranscriptomic sequencing (to assess viral presence, function) with targeted capture-based confirmation.
With other HVP members (e.g., functional interaction awardees), we will study host-viral interactions (Aim 2) via (1) host genomics (for integration); (2) viral tropism studies (using single cell and in vitro infection studies); (3) host response characterization (at the cellular and organism-wide level with proteomics/transcriptomics).
In Aim 3, we will establish a repository of harmonized metadata and molecular information for data sharing in an ethically responsible manner to allow multi-omic connections between longitudinal phenotypes and host-viral characteristics.
We will execute this vision collaboratively within the HVP via (1) a core structure (led by administrative) that addresses biospecimen collection, assay, data analysis/submission, and ethical/legal/social implications that (2) follow a pre-determined series of milestones (predicated on establishing consortium-wide protocols in the initial 6 month planning phase).
V2C2 leadership has (1) published expertise in large sample viral characterization/biological discovery, with extensive preliminary data bearing directly on HVP; (2) cohort epidemiology; (3) extensive consortium experience in NIH, CDC, and Common Fund initiatives.
The effectiveness of V2C2 is augmented by strong community engagement (CCHC), institutional support, and program management staff with experience at the scale of HVP.
Recent developments in technical and bioinformatic capabilities to address viral sequence diversity in a high-throughput context alongside integrated host responses have ushered in the potential for investigating viral presence and consequences at epidemiologic scale.
Here, we establish the Vanderbilt-Coordinated Virus Characterization Center (V2C2) to respond to RFA-RM-23-019 to address the central call of the Human Virome Program (HVP)—to provide a comprehensive, annotated, host-contextualized virome.
The central theme/hypothesis of V2C2 is that unrecognized eukaryotic/prokaryotic viruses in human ecology (1) exhibit important interactions with host biology and flora, with prevalence of viral persistence or integration related to variation in biologically relevant phenotypes in healthy individuals (e.g., obesity, inflammation).
To address this hypothesis, we will study (1) ≈2250 Hispanic/Latinx individuals at the US-Mexico border (ages 8-90; 1750 with 2 serial samples already collected with up to ≈20 years follow-up; 500 with 3 serial samples to be prospectively collected over ≈4 years); (2) ≈200 children (ages 0-5, CANOE-VU) with serial samples (some already collected).
We propose a broad sampling scheme for prospective samples, spanning ocular, nasal, oropharyngeal, plasma, blood (extracellular vesicles, PBMCs, platelets), urine, and stool samples, and accompanying placental and breast milk samples (pediatric cohort), and will prioritize plasma (all samples) and 3 additional sample types (prospective only) based on consortium discussion.
Our host-contextualized viral characterization approach (Aim 1) will include viral whole metagenomic/metatranscriptomic sequencing (to assess viral presence, function) with targeted capture-based confirmation.
With other HVP members (e.g., functional interaction awardees), we will study host-viral interactions (Aim 2) via (1) host genomics (for integration); (2) viral tropism studies (using single cell and in vitro infection studies); (3) host response characterization (at the cellular and organism-wide level with proteomics/transcriptomics).
In Aim 3, we will establish a repository of harmonized metadata and molecular information for data sharing in an ethically responsible manner to allow multi-omic connections between longitudinal phenotypes and host-viral characteristics.
We will execute this vision collaboratively within the HVP via (1) a core structure (led by administrative) that addresses biospecimen collection, assay, data analysis/submission, and ethical/legal/social implications that (2) follow a pre-determined series of milestones (predicated on establishing consortium-wide protocols in the initial 6 month planning phase).
V2C2 leadership has (1) published expertise in large sample viral characterization/biological discovery, with extensive preliminary data bearing directly on HVP; (2) cohort epidemiology; (3) extensive consortium experience in NIH, CDC, and Common Fund initiatives.
The effectiveness of V2C2 is augmented by strong community engagement (CCHC), institutional support, and program management staff with experience at the scale of HVP.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding Agency
Place of Performance
Nashville,
Tennessee
37232
United States
Geographic Scope
Single Zip Code
Vanderbilt University Medical Center was awarded
V2C2: Host-Contextualized Viral Characterization & Interaction
Cooperative Agreement U54AG089326
worth $3,984,525
from the National Institute of Allergy and Infectious Diseases in February 2025 with work to be completed primarily in Nashville Tennessee United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Human Virome Characterization Centers (U54 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 1/28/25
Period of Performance
2/1/25
Start Date
1/31/30
End Date
Funding Split
$4.0M
Federal Obligation
$0.0
Non-Federal Obligation
$4.0M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
U54AG089326
SAI Number
U54AG089326-4137995747
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NN00 NIH NATIONAL INSITUTE ON AGING
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
GYLUH9UXHDX5
Awardee CAGE
7HUA5
Performance District
TN-07
Senators
Marsha Blackburn
Bill Hagerty
Bill Hagerty
Modified: 1/28/25